Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Home
<
List for "N07XX" (15)
–
Sort according to Concentration, Size and Price
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
Riluzole (N07XX02) 3 products
WHO-DDD
DrugBank.ca
IP
CI
Emylif 50 mg
56
179.88
212.05
10 %
film orodispersibile: Riluzolum 50 mg
Zambon Svizzera SA
B / SL
FB
G
IP
CI
Rilutek
56 Tablet(s)
158.66
188.95
10 %
Coated tablets: Riluzolum 50 mg
Sanofi-Aventis
(Suisse) SA
B / SL
FB
G
IP
CI
Teglutik 50mg/10ml
300 ml
101.99
127.35
10 %
Suspension (oral): Riluzolum 50 mg
Effik SA
B / SL
FB
G
Sodium Oxybate (N07XX04) 1 products
WHO-DDD
DrugBank.ca
L
SIP
IP
CI
A
Xyrem 500 mg/ml
Flasche(n) à 180 ml
239.84
277.25
10 %
Solution (oral): Natrii Oxybas 500 mg
UCB-Pharma SA
A+ / SL
FB
G
Amifampridine (N07XX05) 1 products
WHO-DDD
IP
CI
Firdapse
100 Tablet(s)
PR
PR
k.A.
Tablets: Amifampridinum 10 mg
DRAC AG
B
FB
G
Tetrabenazine (N07XX06) 1 products
WHO-DDD
DrugBank.ca
L
SIP
IP
CI
Xenazine
112 Tablet(s)
100.79
126.05
10 %
Tablets: Tetrabenazinum 25 mg
Curatis AG
● 
B / SL
FB
G
Fampridine (N07XX07) 1 products
WHO-DDD
DrugBank.ca
L
IP
CI
Fampyra 10 mg
56
224.09
260.15
10 %
Delayed release tablets: Fampridinum 10 mg
Merz Pharma (Schweiz) AG
B / SL
FB
G
Tafamidis (N07XX08) 2 products
WHO-DDD
L
IP
CI
Vyndaqel 61 mg
30
9422.28
9975.05
10 %
Soft capsules: Tafamidisum 61 mg
Pfizer AG
B / SL
FB
G
IP
CI
Vyndaqel 20 mg
30
PR
PR
k.A.
Soft capsules: Tafamidisum Megluminum 20 mg
Pfizer AG
B
FB
G
Pitolisant (N07XX11) 2 products
WHO-DDD
IP
CI
Wakix 4.5 mg
30
PR
PR
k.A.
Coated tablets: Pitolisantum 4.45 mg
Future Health Pharma
GmbH
B
FB
G
IP
Wakix 18 mg
30
PR
PR
k.A.
Coated tablets: Pitolisantum 17.8 mg
Future Health Pharma
GmbH
B
FB
G
Patisiran (N07XX12) 1 products
WHO-DDD
L
IP
CI
Onpattro 2 mg/ml
7951.47
8466.00
10 %
Concentrate for infusion: Patisiranum 2 mg
Alnylam Switzerland
GmbH
B / SL
FB
G
Edaravone (N07XX14) 3 products
WHO-DDD
IP
CI
Radicava
50 ml
PR
PR
k.A.
Suspension (oral): Edaravonum 105 mg
Mitsubishi Tanabe
Pharma GmbH,
Düsseldorf,
Zweigniederlassung
Lenzburg
B
FB
G
IP
CI
Radicava
2 x 35 ml
PR
PR
k.A.
Suspension (oral): Edaravonum 105 mg
Mitsubishi Tanabe
Pharma GmbH,
Düsseldorf,
Zweigniederlassung
Lenzburg
B
FB
G
IP
Radicava
2
PR
PR
k.A.
Infusion solution: Edaravonum 30mg / 100ml
Mitsubishi Tanabe
Pharma GmbH,
Düsseldorf,
Zweigniederlassung
Lenzburg
B
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2025
©ywesee GmbH
Settings
|
Help
|
FAQ
|
Login
|
Contact
|
Home